BPI
ALNY icon

BFC Planning, Inc.’s Alnylam Pharmaceuticals ALNY Stock Holding History

BFC Planning, Inc.’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Sell
130
-10
-7% -$3.02K ﹤0.01% 1674
2026
Q1 		$46.3K Buy
140
+89
+175% +$30.3K ﹤0.01% 1367
2025
Q4 		$20.3K Sell
51
-1
-2% -$443 ﹤0.01% 1752
2025
Q3 		$23.7K Sell
52
-10
-16% -$4.07K ﹤0.01% 1497
2025
Q2 		$20.2K Buy
62
+15
+32% +$4.15K ﹤0.01% 1495
2025
Q1 		$12.7K Buy
47
+41
+683% +$10.5K ﹤0.01% 1662
2024
Q4 		$1.41K Buy
+6
New +$1.58K ﹤0.01% 2352

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BFC Planning, Inc.'s ALNY Position: Q2 2026 in Review

BFC Planning, Inc. reduced its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, selling an estimated $3.02K and leaving 130 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

BFC Planning, Inc. first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $46.3K in Q1 2026. 796 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • BFC Planning, Inc. held 130 shares of Alnylam Pharmaceuticals worth $39.1K as of Q2 2026.
  • BFC Planning, Inc. sold 10 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.02K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #1674 holding.
  • BFC Planning, Inc. first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • BFC Planning, Inc.'s Alnylam Pharmaceuticals position peaked at $46.3K in Q1 2026.
  • 796 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.